Evidence map›Paper›PMID 42802711›Full record

ArticlePharmacogenomics2026

Process evaluation of a pharmacogenomic informed antidepressant prescribing intervention delivered in primary care: findings from the PRESIDE (PhaRmacogEnomicS in Depression) trial.

Georgia Ramsay, Madeline Luke, Philip Ly, Rachel Brooks, Matthew Thoenig, Elise Dettmann, Jennifer Bibb, Floriana La Rocca, Patty Chondros, Cathrine Mihalopoulos and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacogenomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Georgia RamsayDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Madeline LukeDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Philip LyDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Rachel BrooksDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Matthew ThoenigDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Elise DettmannDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Jennifer BibbDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Floriana La RoccaDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Patty ChondrosDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Cathrine MihalopoulosHealth Economics Group, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Mary Lou ChattertonHealth Economics Group, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Melanie GaleaGenetics Department, Douglass Hanly Moir Pathology, Sonic Healthcare, Sydney, NSW, Australia.
Adrian LaughlinDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Jane GunnFaculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Timothy ChenSydney School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia.
Thomas M PolasekCentre for Medicine Use and Safety, Monash University, Melbourne, Australia.
Victoria J PalmerDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Chad BousmanDepartment of Medical Genetics, University of Calgary, Calgary, AB, Canada.
Sibel SayaDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Jon EmeryDepartment of General Practice and Primary Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMajor depressive disorder (MDD) impacts 300 million people globally, with most people being managed in primary care. Clinical response to antidepressant medications is highly variable. Pharmacogenomics (PGx) may improve prescribers' ability to match an antidepressant medication with patient phenotype, increasing the likelihood of a response.

objectivesThis process evaluation aims to understand factors that impacted PGx intervention implementation in the PRESIDE Trial, conducted in general practices in Victoria, Australia.

methodsAntidepressant prescribing data, evidence of intervention use and qualitative data from interviews with participants were included. Analysis and interpretation of the data were informed by the (UK) Medical Research Council's Framework for Developing and Evaluating Complex Interventions.

resultsWhile clinicians and patients supported PGx informed antidepressant prescribing, documented uptake of the intervention was low, as were antidepressant medication initiations or changes in line with the PGx report. Participants reported a lack of clarity regarding follow-up processes post PGx report return. The impact of COVID-19 during trial implementation included delays to intervention delivery. The provision of mental health care in primary care settings was also impacted.

conclusionsFuture applications of PGx informed antidepressant prescribing would benefit from refined patient selection and ensuring PGx information is available when most useful.

Indexed as

Antidepressive AgentsMajor Depressive DisorderPharmacogeneticsAdultFemaleHumansMaleMiddle AgedPrimary Health CareAntidepressive AgentsantidepressantsAustraliadepressionPharmacogenomicsprimary careprocess evaluation

Identifiers

PMID42802711
PMCPMC13671452

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.